drugset
drugset / Trial / NCT02960035

A Study of the MASEI in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis

NCT02960035 ↗

Phase 4 Completed 96 enrolled Sun Yat-sen University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, multicentral clinical trial to investigate the efficacy of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc fusion protein injection (Yisaipu®) in the treatment of peripheral enthesitis in active axial spondyloarthritis(SpA) patients.

Timeline

Start
2014-04
Primary completion
2016-09
Completion
2018-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg Other
Subject Etanercept Protein / enzyme biologic 50 mg Other

Indications

spondyloarthropathy